Related Experiment Video
Updated: Aug 5, 2025
10:51
The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
Published on: April 10, 2015
12.2K
New nitrosyl ruthenium complexes with combined activities for multiple cardiovascular disorders
Florêncio Sousa Gouveia Júnior1, João Alison de Moraes Silveira2,3, Thais Muratori Holanda2,3
1Laboratory of Bioinorganic Chemistry, Department of Organic and Inorganic Chemistry, Federal University of Ceara, 60455-760, Fortaleza-CE, Brazil. eduardohss@dqoi.ufc.br.
Dalton Transactions (Cambridge, England : 2003)
|March 27, 2023
Summary
New nitrosyl ruthenium complexes release nitroxyl (HNO), demonstrating therapeutic potential. These compounds show promise for treating cardiovascular diseases like atherosclerosis due to their vasodilating and antioxidant effects.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Materials Science
Background:
- Nitrosyl ruthenium complexes are explored for therapeutic nitric oxide (NO) and nitroxyl (HNO) release.
- Developing novel metal-based compounds for targeted therapeutic applications is crucial.
Purpose of the Study:
- To synthesize and characterize novel polypyridinic nitrosyl ruthenium complexes.
- To investigate the potential of these complexes as therapeutic agents for cardiovascular conditions.
Main Methods:
- Synthesis of *cis*-[Ru(NO)(bpy)2(L)]n+ complexes with imidazole derivatives.
- Characterization using spectroscopic (XANES/EXAFS) and electrochemical techniques, alongside DFT calculations.
- Biological validation through HIF-1α detection and assessment of vasodilating and antioxidant properties.
Main Results:
- Two novel nitrosyl ruthenium complexes were successfully synthesized and characterized.
- Complexes were shown to release nitroxyl (HNO) upon reaction with thiols.
- Biological assays confirmed nitroxyl release and demonstrated vasodilating and antioxidant activities.
Conclusions:
- The developed nitrosyl ruthenium compounds exhibit promising therapeutic potential.
- These complexes may serve as effective agents for treating cardiovascular diseases, including atherosclerosis.
- Further research is warranted to explore their full therapeutic capabilities.
More Related Videos
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
674
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
674
01:23Antihypertensive Drugs: Vasodilators
590
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
590
01:202° Amines to N-Nitrosamines: Reaction with NaNO2
4.4K
Secondary amines react with nitrous acid to form N-nitrosamines, as depicted in Figure 1. Nitrous acid, a weak and unstable acid, is formed in situ from an aqueous solution of sodium nitrite and strong acids, such as hydrochloric acid or sulfuric acid, in cold conditions. In the presence of an acid, the nitrous acid gets protonated. The subsequent loss of water results in the formation of the electrophile known as nitrosonium ion.
4.4K
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
131
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
131
01:29Preparation of Amines: Reduction of Oximes and Nitro Compounds
3.9K
Oximes can be reduced to primary amines using catalytic hydrogenation, hydride reduction, or sodium metal reduction. The reduction of aliphatic and aromatic nitro compounds to primary amines takes place by either catalytic hydrogenation or by using active metals like Fe, Zn, and Sn in the presence of an acid.
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
Though catalytic hydrogenation can reduce nitrobenzenes, the reduction is nonselective in the presence of other functional groups. For instance, if nitrobenzene contains an aldehyde group,...
3.9K
01:46Electron Transport Chain: Complex I and II
14.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.7K